Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes

被引：0
|
作者：
Goss, Christopher H. [1 ,2 ,3 ]
Vandevanter, Donald R. [4 ]
机构：
[1] Univ Washington, Dept Med, Seattle, WA 98195 USA
[2] Univ Washington, Dept Pediat, Seattle, WA 98195 USA
[3] Seattle Children s Res Inst, CF Therapeut Dev Network Coordinating Ctr, Seattle, WA 98101 USA
[4] Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2024年 / 63卷 / 06期
基金：
美国国家卫生研究院;
关键词：
PULMONARY EXACERBATIONS; ANTIBIOTIC-TREATMENT; TRIAL; PLACEBO;
D O I：
10.1183/13993003.00858-2024
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Evidence continues to build regarding management of pulmonary exacerbation in cystic fibrosis. This editorial comments on the work by Waters and colleagues, noting evidence continues to build regarding the lack of efficacy of steroids in exacerbation. © 2024 European Respiratory Society. All rights reserved.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Noninvasive Ventilation in Cystic Fibrosis: Clinical Indications and Outcomes in a Large UK Adult Cystic Fibrosis Center
    Spoletini, Giulia
    Pollard, Kim
    Watson, Ruth
    Darby, Michael J.
    Johnstone, Annette
    Etherington, Christine
    Whitaker, Paul
    Clifton, Ian J.
    Peckham, Daniel G.
    RESPIRATORY CARE, 2021, 66 (03) : 466 - 474
  • [32] Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation
    Sanders, D. B.
    Khan, U.
    Heltshe, S. L.
    Skalland, M.
    West, N. E.
    VanDevanter, D. R.
    Goss, C. H.
    Flume, P. A.
    JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (04) : 574 - 580
  • [33] Bacteraemia and fungaemia in cystic fibrosis patients with febrile pulmonary exacerbation: a prospective observational study
    Joerg Grosse-Onnebrink
    Florian Stehling
    Eva Tschiedel
    Margarete Olivier
    Uwe Mellies
    Rene Schmidt
    Jan Buer
    Peter-Micheal Rath
    Joerg Steinmann
    BMC Pulmonary Medicine, 17
  • [34] COVID-19 outcomes in people with cystic fibrosis
    Burgel, Pierre-Regis
    Goss, Christopher
    CURRENT OPINION IN PULMONARY MEDICINE, 2021, 27 (06) : 538 - 543
  • [35] Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
    Sherwin, Catherine M. T.
    Zobell, Jeffery T.
    Stockmann, Chris
    McCrory, Bradley E.
    Wisdom, Millie
    Young, David C.
    Olson, Jared
    Ampofo, Krow
    Spigarelli, Michael G.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 (01) : 71 - 79
  • [36] Patients with cystic fibrosis and normoglycemia exhibit diabetic glucose tolerance during pulmonary exacerbation
    Sc, Noa Nezer M.
    Shoseyov, David
    Kerem, Eitan
    Zangen, David Haim
    JOURNAL OF CYSTIC FIBROSIS, 2010, 9 (03) : 199 - 204
  • [37] Socioeconomic status and health outcomes: cystic fibrosis as a model
    Oates, Gabriela R.
    Schechter, Michael S.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (09) : 967 - 977
  • [38] The airway microbiome in cystic fibrosis and implications for treatment
    Zemanick, Edith T.
    Sagel, Scott D.
    Harris, Jonathan K.
    CURRENT OPINION IN PEDIATRICS, 2011, 23 (03) : 319 - 324
  • [39] Update on treatment of pulmonary exacerbations in cystic fibrosis
    Smyth, Alan
    CURRENT OPINION IN PULMONARY MEDICINE, 2006, 12 (06) : 440 - 444
  • [40] Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis
    Hurley, Matthew
    Smyth, Alan
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2012, 6 (06) : 363 - 373
12345